Date: 2011-12-16
Type of information: R&D agreement
Compound: new anticancer biotherapies
Company: Transgene (France) French League against Cancer (France)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease: cancer
Details: Transgene and the Ligue nationale contre le cancer (the French league against cancer) an association with a recognized status of public interest, have signed a partnership agreement to accelerate the research and development of new anticancer biotherapies. As early as 2000, the League initiated, financed and developed an ambitious programme, named “CIT“ (for Carte d’Identité des Tumeurs, or identity card of tumours) in order to analyze the genes and chromosomal alterations in numerous cancers. The ultimate objective is the ability to better diagnose, predict disease evolution and response to treatments and to improve the therapeutic follow-up for each individual patient. CIT allows, notably, to identify biomarkers or therapeutic targets linked to peculiar or tumour-specific cellular mechanisms, following the example of TG4010, a therapeutic vaccine currently in development by Transgene, that targets the MUC1 tumour antigen present in several types of cancers (lung, breast, prostate…).By bringing together their expertise, the League and Transgene aim at accelerating the development of specific drugs for certain tumours. This is the first collaboration between an important association fighting cancer and a biotechnology company. This collaboration will allow identifying cancer-specific membrane targets from gene expression data collected by the League on over 4,800 tumours. The partners vow to be exemplary regarding their respective missions, so as to put the patient back at the centre of the R&D operations and to implement at the earliest the results of their collaboration.
Financial terms:
Latest news:
